| AIMP2-DX2, a splicing variant of tumor suppressor AIMP2, can be a therapeutic target to control chemoresistant epithelial ovarian cancer . | ovarian, |
| Ratio of Autoantibodies of Tumor Suppressor AIMP2 and Its Oncogenic Variant Is Associated with Clinical Outcome in Lung Cancer | lung, |
| functional significance of AIMP2 in determination of cell proliferation and death, and as a haploinsufficient tumor suppressor. | None |
| Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression. | None |
| These data indicate monomer-dimer equilibrium of AIMP2-DX2 in solution. These results form the basis for the structure-function study of oncogenic AIMP2-DX2. | None |